Eli Lilly saw an improvement in its IBD SmartSelect Composite Rating Monday, from 90 to 96.
Looking For The Best Stocks To Buy And Watch? Start Here
The revised score means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength.
Eli Lilly is currently forming a consolidation, with a 972.53 entry. Look for the stock to break out in volume at least 40% higher than normal.
The stock has a 93 EPS Rating, which means its recent quarterly and longer-term annual earnings growth tops 93% of all stocks.
Its Accumulation/Distribution Rating of B- shows moderate buying by institutional investors over the last 13 weeks.
In Q1, the company reported 29% EPS growth. Sales were flat, matching the prior quarter's 45%.
Eli Lilly holds the No. 1 rank among its peers in the Medical-Diversified industry group. Abbott Laboratories and AstraZeneca ADR are also among the group's highest-rated stocks.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
